

Extract of Audited Financial Results for the Quarter And Year Ended 31st March, 2016

Particulars	(Rs. In Lacs)		
	Quarter Ended 31/03/2016	Year Ended 31/03/2016	Quarter Ended 31/03/2015
	(Audited)	(Audited)	(Audited)
1. Total Income From Operations (net)	127.57	173.87	35.06
2. Net Profit/(loss) from ordinary activities after tax	25.20	42.68	30.15
3. Net Profit/(loss) for the period after tax	25.20	42.68	30.15
4. Equity Share Capital			
5. Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)		42.68	
6. Earning per share (before extraordinary items) (Face Value of Rs 10 each not annualized)			
a. Basic	0.47	0.80	0.56
b. Diluted	0.47	0.80	0.56
7. Earning per share (after extraordinary items) (Face Value of Rs 10 each not annualized)			
a. Basic	0.47	0.80	0.56
b. Diluted	0.47	0.80	0.56

Note:

- The above is an extract of the detailed format of financial results filed with the stock exchange under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Full format of the above extract is available on the Website of BSE (www.bseindia.com) and as well as on company's website (www.parabinfraltd.com)

For and on the behalf of board of directors

Sd/-
Amrit Gandhi
Managing Director
DIN- 02870947

Mumbai
Date: 26/05/2016

ADINATH BIO-LABS LIMITED
 CIN: L24230WB1982PLC34492

Registered Office: 4 N. S. Road, 1st floor, Kolkata-700 001
 Email: info@adinathbio.com, Website: www.adinathbio.com

EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE 4TH QUARTER AND YEAR ENDED 31ST MARCH 2016

Sl No	Particulars	(Rs. in Lakhs)			
		Quarter Ended 31.03.16	Quarter Ended 31.12.15	Year Ended 31.03.16	Year Ended 31.03.15
1	Total income from operations (net)	18.70	17.81	80.53	135.23
2	Net Profit / (Loss) from ordinary activities after tax	1.06	1.00	14.37	16.50
3	Net Profit / (Loss) for the period after tax (after Extraordinary items)	1.06	1.00	14.37	16.50
4	Equity Share Capital (Face Value of the Share shall be indicated)(Rs.)	2207.43	2207.43	2207.43	2207.43
5	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	722.61	708.24
6	Earnings Per Share (before extraordinary items) (of ₹ 1/- each)				
	(a) Basic	0.000	0.000	0.007	0.007
	(b) Diluted	0.000	0.000	0.007	0.007
7	Earnings Per Share (after extraordinary items) (of ₹ 1/- each)				
	(a) Basic	0.000	0.000	0.007	0.007
	(b) Diluted	0.000	0.000	0.007	0.007

Note:

- The above is an extract of the detailed format of Quarterly/Nine Months Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Nine Months Financial Results are available on the Stock Exchange websites viz. www.bseindia.com & www.cse-india.com. The same is also available on the Company's website viz. www.adinathbio.com

By Order of the Board
 For Adinath Bio-Labs Limited
 Abhishek Kumar Jain
 Whole Time Director
 DIN: 00054582

Place : Kolkata.
 Dated : 25.05.2016

Particulars

(1)

Particulars	(1)
A. EQUITY AND LIABILITIES	
1. Shareholders' Funds	
(a) Share Capital	
(b) Reserves and Surplus	26,
Sub-total - Shareholders' Funds	27,
2. Share application money pending allotment in respect of Joint Venture	
3. Minority Interest	
4. Share Warrants in respect of Joint Venture	
5. Non-Current Liabilities	
(a) Long-Term Borrowings	13,
(b) Deferred Tax Liabilities (Net)	2,
(c) Other Long-Term Liabilities	
(d) Long-Term Provisions	1,
Sub-Total - Non-Current Liabilities	17,
6. Current Liabilities	
(a) Short-Term Borrowings	
(b) Trade Payables	8,
(c) Other Current Liabilities	20,
(d) Short-Term Provisions	3,
Sub-Total - Current Liabilities	31,
TOTAL - EQUITY AND LIABILITIES	75,
B. ASSETS	
1. Non-Current Assets	
(a) Fixed Assets (Net)	36,
(b) Goodwill on consolidation	
(c) Non-Current Investments	7,
(d) Deferred Tax Assets (Net)	
(e) Long-Term Loans and Advances	3,
(f) Other Non-Current Assets	
Sub-Total - Non-Current Assets	47,
2. Current Assets	
(a) Current Investments	5,
(b) Inventories	13,
(c) Trade Receivables	2,
(d) Cash and Cash Equivalents	2,
(e) Short-Term Loans and Advances	1,
(f) Other Current Assets	4,
Sub-Total - Current Assets	28,
TOTAL - ASSETS	75,

NOTES:

- The market sales for the financial year ended when compared to 34.45 MMT achieved during - Retail (12.37%) and LPG (8.07%) partly off RLNG (-11.98%).
- The Average Gross Refining Margin (GRM) during is **6.59 USD per barrel** (April - March 2015: Refining Margin (GRM) for the three months **barrel** (January - March 2015: 7.85 USD per barrel)
- As advised by the Ministry of Petroleum & Natural Gas, Government of India, the Corporation has received compensation towards sharing of under-recovery of products as follows:
 - ₹ 19,801 lakhs for the current financial year discount on crude oil / products purchased for adjusted against the purchase cost.
 - ₹ 1,59,849 lakhs compensation advised by the Government of India for the current financial year (April - March 2015) on Net Sales/Income from Operations. The net under-recovery absorbed by the Corporation (April - March 2015: ₹ 48,738 lakhs) on sale of products.
- Other expenses for the financial year ended towards loss on account of foreign currency transactions financial year ended 31st March 2015. Other Income on account of foreign currency transactions is ₹ 1,59,849 lakhs.
- Pursuant to the notification dated 29th August 2015, the Corporation has complied with the Part C of Schedule II of the Companies Act, 2013. This has resulted in higher depreciation.

